Advertisement
Horizon Therapeutics To Buyback Up To $500 Mln Of Ordinary Shares
(RTTNews) - Biotechnology company Horizon Therapeutics plc (HZNP) today announced that its Board of Directors authorized the repurchase of up to $500 million of the Company's ordinary shares.
Under the program, the Company may repurchase ordinary shares from time to time on the open market or through privately negotiated transactions or structured repurchase transactions.
As of June 30, 2022, the Company had cash and cash equivalents of $1.89 billion. The Company expects to fund the repurchase of its ordinary shares under the program with existing cash and cash equivalents.
read more
Amgen, Horizon Therapeutics Reach Settlement On FTC Lawsuit; Seeks To Close Acquisition In Q4
Amgen (AMGN) and Horizon Therapeutics plc (HZNP) announced Friday the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's $27.8 billion acquisition of Horizon.
RTTNews
|
727 दिनों पहले
Horizon Says UPLIZNA Approved By Brazilian Health Regulatory Agency As Monotherapy For NMOSD
Biotechnology company Horizon Therapeutics plc (HZNP) announced Tuesday that the Brazilian Health Regulatory Agency (ANVISA) has approved UPLIZNA as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+.
RTTNews
|
982 दिनों पहले
Xeris Biopharma Inks Research Collaboration With Horizon Therapeutics To Develop Teprotumumab
Biopharmaceutical company Xeris Biopharma Holdings, Inc. (XERS) announced Wednesday that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (HZNP).
RTTNews
|
1009 दिनों पहले
Horizon Says Phase 2 Trial Of Dazodalibep To Treat Sjögren's Syndrome Met Primary Endpoint
Horizon Therapeutics plc (HZNP) announced Monday that its Phase 2 trial evaluating dazodalibep for the treatment of Sjögren's syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity. Sjögren's syndrome is a disease with no FDA-approved treatments available.
RTTNews
|
1081 दिनों पहले
DAX Retreats After Firm Start, Down Marginally
After opening on a strong note thanks to easing AI slowdown fears after Nvidia's impressive results, the German market retreated and slipped into negative territory on Thursday. Despite paring some early gains, auto stocks remain fairly well up in positive territory.
RTTNews
|
23 मिनटों पहले
Swiss Franc Rises Against Majors
The Swiss franc strengthened against other major currencies in the European session on Thursday.
RTTNews
|
38 मिनटों पहले
Sensex, Nifty Retreat On US Tariff Worries
Indian shares fell sharply on Thursday as traders waited to see how New Delhi responds to pressure from Washington to stop buying Russian oil after the 50 percent tariffs levied by the U.S. on Indian goods came into effect on Wednesday.
RTTNews
|
43 मिनटों पहले
Bank Of Korea Stands Pat On Rates, Lifts 2025 Growth Outlook
The Bank of Korea left its interest rate unchanged on Thursday as economic growth improved moderately despite high uncertainty surrounding the outlook. The Monetary Policy Board decided to hold the Base Rate at 2.50 percent. The central bank had previously lowered the benchmark rate by a quarter-point each in May and February.
RTTNews
|
50 मिनटों पहले
